BeiGene has opened its new flagship US biologics manufacturing and clinical research and development (R&D) facility, built with an investment of $800m in Hopewell, New Jersey.
Located at the Princeton West Innovation Campus, the facility is expected to expand the oncology company’s presence and deliver medicines to more cancer patients around the world.
The 42-acre facility features advanced biologics manufacturing capabilities and a clinical research and development centre.
The site offers scalable production capacity to meet current and future demands for its cancer therapies. This includes more than 30 molecules that BeiGene has in clinical or commercial stages.
According to BeiGene, the New Jersey site includes around 400,000ft2 for commercial-stage biologic pharmaceutical manufacturing, with space for future expansion to accommodate the firm’s developing pipeline.
In addition, the facility enhances the firm’s capabilities in late-stage research and clinical development.
BeiGene co-founder, chairman and CEO John Oyler said: “BeiGene has experienced unprecedented global growth, and the addition of our facility at the Princeton West Innovation Campus adds manufacturing and clinical development capabilities that will further strengthen our differentiated strategy which leverages speed, efficiency and technology to advance quality medicines faster for patients.”
BeiGene’s investment in the new New Jersey facility marks the completion of a three-year project to expand the company’s integrated manufacturing and research and development operations in the US.
By the end of 2025, the drugmaker plans to create hundreds of skilled jobs at the site.
BeiGene has modalities including targeted degraders, antibody drug conjugates (ADCs), monoclonal antibodies, and traditional small molecules.
The New Jersey facility builds on the existing infrastructure of the oncology company, enabling large-scale production that reduces costs and enhances supply chain resilience.
New Jersey Governor Phil Murphy said: “The opening of BeiGene’s flagship campus underscores our commitment to fostering innovation and creating high-tech jobs in the Garden State.
“We look forward to the positive impact BeiGene will have on our economy and the advancements they will bring to cancer treatment.”
